BioPorto A/S BIOPOR

September 28, 2026News release Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7 As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, we invite you to join us for an afternoon focused on the key drivers that may shape the Company's future.At the event, management will provide an update on BioPorto's commercial progress, regulatory initiatives, strategic priorities, and path toward sustainable growth and cash flow

September 24, 2026News release Reminder: Register Now | Unlocking the Growth - BioPorto Investor Meeting, October 7 As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, we invite you to join us for an afternoon focused on the key drivers that may shape the Company's future.At the event, management will provide an update on BioPorto's commercial progress, regulatory initiatives, strategic priorities, and path toward sustainable growth and cas

September 16, 2026News Release First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study. COPENHAGEN, DENMARK, September 16 , 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced the enrollment of the first patient as part of the ProNephro AKI U.S. Adult Urine NGAL Validation Study, marking an important milestone in the company’s clinical efforts to expand ProNephro AKI (NGAL) to the adult population. The

September 14, 2026News release Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7 As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, we invite you to join us for an afternoon focused on the key drivers that may shape the Company's future.At the event, management will provide an update on BioPorto's commercial progress, regulatory initiatives, strategic priorities, and path toward sustainable growth and cash flow

August 20, 2026Announcement no. 14 BioPorto announces Interim Results for the Second Quarter and First half of 2026 Copenhagen, Denmark, August 20, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), today announced Interim financial results for the second quarter and first half of 2026. BioPorto delivered continued underlying NGAL growth of 34% at constant exchange rates, excluding the previously announced voluntary recall impact, while advancing the U.S.

August 18, 2026Press Release BioPorto activates the first US clinical site as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study. COPENHAGEN, DENMARK, August 18, 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced the activation of the first U.S. clinical site for the ProNephro AKI U.S. Adult Urine NGAL Validation Study, marking an important milestone in the company’s clinical efforts to expand ProNephro AKI (NGAL) to adult patients. The ProNephro AKI U.S.

BioPorto A/S to host an investor webcast on the results for the first half of 2026 COPENHAGEN, DENMARK, August 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), announced today that CEO Carsten Buhl and CFO Klaus Juhl Wulff will present financial results for the first quarter of 2026 at a webcast for investors on August 20, 2026 at 02:00 PM CET. Registration for the presentation is now open, and participants can submit questions in advance. Please register at the f

June 15, 2026 Announcement no. 13 Grant of Warrants Copenhagen, Denmark, June 15, 2026, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today decided to issue a total of 1,200,000 warrants to members of the Company’s Senior Leadership Team. Each warrant entitles the holder the right to subscribe for one share in BioPorto at an exercise price of DKK 1.15 per share. The warrants are issued in accordance with section 18 a of the Articles of A

June 9, 2026Announcement no. 12 BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback COPENHAGEN, DENMARK, June 9, 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announces its intention to initiate the ProNephro AKI™ U.S. Adult Urine NGAL Validation Study. The initiation follows the constructive feedback from the U.S. Food and Drug Administration (“FDA”) on the Company’s pre-submission request filed on March 31, 2026, and wil

As Europe's major indices experience a downturn amid rising geopolitical tensions and inflationary pressures, investors are seeking opportunities in less conventional areas of the market. Penny stocks, often associated with smaller or newer companies, remain an intriguing option despite their somewhat outdated moniker. These stocks can offer growth potential at lower price points when backed by strong financials and solid fundamentals.

May 12, 2026 News release BioPorto A/S to host an investor webcast on the results for the first quarter of 2026 COPENHAGEN, DENMARK, May 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), announced today that CEO Carsten Buhl and CFO Klaus Juhl Wulff will present financial results for the first quarter of 2026 at a webcast for investors on May 21, 2026 at 11:00 AM CET. Registration for the presentation is now open, and participants can submit questions in advance. P

April 24, 2026Announcement no. 10 Resolutions of the Annual General Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, April 24, 2026, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH: BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today held its Annual General Meeting with the following results: Item 1 - The Board's report on the Company’s activities during the past year was noted by the Annual General Meeting. Item 2 –

Millrock Technology ("Millrock"), a provider of lyophilization and advanced freeze-drying solutions for the life sciences and biopharmaceutical industries, today announced the appointment of Neil A. Goldman, CPA, as Chief Financial Officer.

April 13, 2026 Company Announcement No. 8 Major Shareholder Announcement COPENHAGEN, DENMARK and BOSTON, MA, USA, 13 April 2026 – BioPorto A/S (“BioPorto” or the “Company”) (CPH: BIOPOR) hereby announces, pursuant to sections 30 and 38 of the Danish Capital Markets Act, that the Company has received a major shareholder notification from Martin Bundgaard. As of 8 April 2026, Martin Bundgaard has exceeded the 5% threshold of the total share capital and voting rights in BioPorto A/S. As of 8 April

April 8, 2026 Company Announcement No. 7 BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC COPENHAGEN, DENMARK and BOSTON, MA, USA, April 8, 2026 – BioPorto A/S (“BioPorto” or the “Company”) (CPH: BIOPOR) today announces the successful signing and simultaneous closing of an agreement to divest its antibody business to Janel Life Sciences LLC, a subsidiary of the Janel Corporation. The transaction encompasses BioPorto’s antibody business and represent

March 31, 2026Announcement no. 6 BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis COPENHAGEN, DENMARK, 31 March 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced that it has formally submitted its FDA pre‑submission package to the U.S. Food and Drug Administration (FDA). This marks an important regulatory milestone for the Company and follows the positive preliminary analysis recently completed fo

March 31, 2026News Release KDIGO publishes 2026 Clinical Practice Guideline Draft for Acute Kidney Injury and Acute Kidney Disease COPENHAGEN, DENMARK, 31 March 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced that the KDIGO 2026 Clinical Practice Guideline Draft for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) has been published, which introduces the first major update to global AKI guidelines since 2012. The draft highlights substantial advances in early